Cyproterone acetate treatment of females with hyperandrogenism.
Five females with idiopathic hirsutism, ten with adrenogenital syndrome, four with acne vulgaris, and three with Stein-Leventhal syndrome were treated for nine months with large or small doses of cyproterone acetate (100 or 2 mg daily, respectively) in combination with oestrogen. The drug had a good effect on the acne vulgaris and moderated the hirsutism. In the various patient groups the serum testosterone level was decreased to between 58.6% (+/- 28.7% S.E.) and 10.8% (+/- 8.2% S.E.) of the basal value. No essential difference in effectiveness was observed between the large and small doses. Based on study of the side-effects, it is recommended that laboratory liver tests are used for control.
D015068:17-Ketosteroids / Q000652:urine; D000152:Acne Vulgaris / Q000188:drug therapy*; D000293:Adolescent; D000312:Adrenal Hyperplasia, Congenital / Q000188:drug therapy*; D000328:Adult; D000410:Alanine Transaminase / Q000097:blood; D001219:Aspartate Aminotransferases / Q000097:blood; D003534:Cyproterone / Q000031:analogs & derivatives* / Q000627:therapeutic use; D017373:Cyproterone Acetate; D005260:Female; D006628:Hirsutism / Q000188:drug therapy*; D006801:Humans; D006854:Hydrocortisone / Q000097:blood; D011085:Polycystic Ovary Syndrome / Q000188:drug therapy*; D013739:Testosterone / Q000097:blood
D015068:17-Ketosteroids; D013739:Testosterone; D017373:Cyproterone Acetate; D003534:Cyproterone; D001219:Aspartate Aminotransferases; D000410:Alanine Transaminase; D006854:Hydrocortisone